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Background-—Dementia is a growing health burden of an aging population. This study aims to evaluate the prevalence of cognitive
impairment and the predictors of cognitive decline at 1 year in older patients with non-ST–elevation acute coronary syndrome
undergoing invasive care.
Methods and Results-—Older patients with non-ST–elevation acute coronary syndrome were recruited into the ICON1 study.
Cognition was evaluated using Montreal Cognitive Assessment. The composite major adverse cardiovascular events comprised
death, myocardial infarction, unplanned revascularization, stroke, and signiﬁcant bleeding at 1 year. Of 298 patients, 271 had
cognitive assessment at baseline, and 211 (78%) had follow-up Montreal Cognitive Assessment at 1 year. Mean age was
80.54.8 years. There was a high prevalence (n=130, 48.0%) of undiagnosed cognitive impairment (Montreal Cognitive
Assessment score <26) at baseline. Cognitive impairment patients were more likely to reach major adverse cardiovascular events
by Kaplan–Meier analysis (P=0.047). Seventy-four patients (35.1%) experienced cognitive decline (Montreal Cognitive Assessment
score drop by ≥2 points) at 1 year. Recurrent myocardial infarction was independently associated with cognitive decline at 1 year
(odds ratio 3.19, 95% conﬁdence interval 1.18–8.63, P=0.02) after adjustment for age and sex.
Conclusions-—In older patients undergoing invasive management of non-ST–elevation acute coronary syndrome, there is a high
prevalence of undiagnosed cognitive impairment at baseline. Recurrent myocardial infarction is independently associated with
cognitive decline at 1 year.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT01933581. ( J Am Heart Assoc. 2019;8:
e011218. DOI: 10.1161/JAHA.118.011218.)
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O ur population is rapidly aging. Dementia is a growinghealth burden of an aging population. Cognitive impair-
ment (CI) is known to share many common risk factors with
coronary artery disease (CAD) including age, smoking,
genetics, hypertension, diabetes mellitus, dyslipidemia, meta-
bolic syndrome, and inﬂammation.1 The Cardiovascular Health
Study reported a higher incidence of dementia in people with
prevalent CAD.2 The Rotterdam study showed higher inci-
dences of dementia in those with prior myocardial infarction
(MI).3 The Bronx Aging Study found that women aged
>75 years with a history of MI were more likely to develop
dementia than those with no history of MI.4 Possible
mechanisms leading to cognitive impairment and dementia
in patients with CAD might include cerebral hypoperfusion
and ischemic brain injury as a result of cerebrovascular
atherosclerosis.1
Older patients compared with young individuals experience
more non-ST–elevation acute coronary syndrome
(NSTEACS).5,6 No previous study has evaluated whether the
incident of NSTEACS or its management using invasive care
leads to decline in cognitive function in older patients. The
aim of this prospective cohort study is to determine the
prevalence of cognitive impairment, the degree of cognitive
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decline over time, and to identify independent predictors of
cognitive decline in older patients undergoing invasive
management for NSTEACS.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Study Design
The ICON-1 study (A Study to Improve Cardiovascular Outcomes
in High Risk Patients With Acute Coronary Syndrome) is a
multicenter prospective cohort study consisting of older patients
undergoing invasive management (coronary angiography with a
view to revascularization) for NSTEACS. Ethical approval was
gained from the appropriate Local Ethics Committee andNational
Research Ethics Service (NRES; 12/NE/0160). Written and
informed consent was received from all participants before
enrollment into the study.Details of the study design canbe found
in the previously published ICON1 study protocol.7 Between
November 2012 and December 2015, patients aged ≥65 years
undergoing invasive management for NSTEACS, referred to 2
tertiary cardiac centers were recruited with 1-year follow-up
completed in December 2016. Exclusion criteria were cardiac
arrest, ventricular arrhythmia or cardiogenic shock, moderate to
severe valvular heart disease, active infection, malignancy with
expected survival <1 year, and lack of capacity to consent.8
Study Procedure, Measures of Cognitive
Impairment, Frailty, and Comorbidity
All study participants underwent guideline-directed medical
therapy, and invasive management at the discretion of the
operating consultant interventional cardiologist. At baseline,
participant demographics, medical history, and details of
invasive management (coronary angiography, percutaneous
coronary intervention, periprocedural complications) were
obtained. Additional information on patient’s cardiovascular
status was assessed by ascertaining the New York Heart
Association functional classiﬁcation and Canadian Cardiovas-
cular Society angina grade.
Cognitive function was assessed by using the Montreal
Cognitive Assessment (MoCA) which has been developed and
validated as a screening tool to accurately detect levels of CI.
As a screening test, MoCA provides a practical assessment in
the clinical setting to identify older adults who present with
mild cognitive impairment. The MoCA assessment consists of
tests in 7 domains (orientation, attention, recall, naming,
visuospatial, language, and abstract reasoning) to give a
representation of a person’s current cognitive ability.9 One
point was used for education adjustment, in which an
additional point can be added to the total score if patient’s
education years ≤12. It is administered over 10 minutes to
patients at baseline during index NSTEACS hospital stay and
at 1-year follow-up clinic. It gives a score ranging from 0 to
30, and a cut-off of 26 points has been used with scores ≥26
being normal, and scores <26 being cognitively impaired.
Scores <26 can be subdivided to reﬂect degree of cognitive
impairment (score 23–25: mild cognitive impairment; score
17–22: moderate cognitive impairment; scores ≤16: demen-
tia).9 A reduction in total MoCA score of 2 and more points is
considered signiﬁcant cognitive decline.10 Patients who had a
reduction of ≥2 points in MoCA at 1-year follow-up from
baseline score are deﬁned as “decliners,” all the other
patients with a MoCA score available at 1 year are “nonde-
cliners.”
All patients underwent assessment for frailty at baseline,
using the Fried Frailty Criteria derived from the Cardiovascular
Health Study, which consists of subjective and objective
assessment in 5 domains: weight loss, exhaustion, physical
inactivity, weakness, or slow walking.11 Participants score 1
point for each criterion, a sum score of 0 to 2 is categorized,
as nonfrail, and ≥3 as frail. The Charlson Co-morbidity Index
was calculated taking into account age; this is based on a
weighted index of the number and severity of comorbid
medical conditions.12 Laboratory blood testing including full
blood count, urea and electrolytes, high-sensitivity cardiac
troponin T, and high-sensitivity C-reactive protein were
performed in all patients at baseline.
Clinical Outcomes and Follow-Up
The major adverse cardiovascular events (MACE) outcome
was a composite of death, nonfatal MI, urgent unplanned
repeat revascularization, stroke, and signiﬁcant bleeding at 1
Clinical Perspective
What Is New?
• There is a high prevalence of cognitive impairment in older
patients with non-ST–elevation acute coronary syndrome
undergoing invasive care.
• Recurrent myocardial infarction is independently associated
with cognitive decline at 1 year.
What Are the Clinical Implications?
• More aggressive contemporary therapeutic strategies to
prevent recurrent events might play a role in reducing
cognitive decline and subsequently delaying progression
into dementia, and older patients should not be denied
advanced care with contemporary treatment strategies.
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year. For time to MACE, only the ﬁrst occurring event was
counted. Signiﬁcant bleeding was deﬁned as per Bleeding
Academic Research Consortium criteria. All 1-year outcomes
were ascertained at follow-up appointment with the patient in
the clinic, or by telephone consultation with the patient if
unable to attend the clinic, or via interrogation of summary
care records obtained from the patient’s regular primary care
physician. Discharge summaries provided by the patient or by
their primary care physician and tertiary center electronic
patient records were accessed to identify repeat revascular-
ization procedures, or hospital readmission.
Statistical Methods
Baseline characteristics were summarized descriptively both
overall and stratiﬁed by CI status using mean (SD), median
(interquartile range), or frequency (percentage) as appropri-
ate. Baseline characteristics and procedural details were
compared between those with and without cognitive impair-
ment using the Student t test or Mann–Whitney U for
continuous variables and the v2 test or Fisher exact test for
categorical variables. Baseline and follow-up MoCA scores
were compared using paired t test.
For time to event data, the Kaplan–Meier method was used
to estimate survival function (ie, fraction of patients free of
MACE for a certain amount of time from baseline) and
comparisons between groups were made using the Log-rank
test. Hazard ratios were estimated using Cox regression
models. The proportional hazard assumption was tested.
Logistic regression models were used to estimate the
association of multiple covariates with cognitive decline, with
the stepwise backward selection likelihood ratio method.
Because of the nature of these hypothesis-generating anal-
yses, a 2-tailed P<0.05 was used as the threshold for
statistical signiﬁcance. The Statistical Package for the Social
Sciences (SPSS, version 23.0; IBM, New York) software was
used for all statistical analyses.
Results
In total, 298 eligible patients were recruited to ICON-1. Of
these, 271 (90.9%) participants underwent cognitive assess-
ment using MoCA test at baseline, and 130 (48.0%) had
cognitive impairment. A ﬂow diagram of patient recruitment to
ICON-1 is presented in Figure 1. The mean age of study
participants was 80.54.8 years; 169 (62.4%) were
male. With regard to diagnosis, 219 patients (80.8%) had
non-ST–elevation myocardial infarction; 52 patients (19.2%)
had troponin-negative unstable angina. All participants under-
went coronary angiography; 225 (83%) underwent revascular-
ization via percutaneous coronary intervention, 10 (3.7%)
underwent coronary artery bypass graft, and the remaining 36
(13.3%) were managed with optimal medical therapy only.
Prevalence of CI
There is a high prevalence (n=130, 48.0%) of undiagnosed CI
in this older patient group with NSTEACS determined by a
MoCA score <26. Of these 130 patients, 92 (70.8%) had mild
CI, 31 (23.8%) had moderate impairment, and 7 (5.4%) had
severe impairment that can be considered in the dementia
category. The baseline characteristics of the study population
are presented in Table 1.
Presentation and Management of NSTEACS by
Cognition Phenotype
CI patients were more likely to be managed with medical
therapy only (P=0.04), and had more left mainstem disease
(P=0.03). CI patients received less contrast load during a
procedure compared with the normal cognition group
(P=0.006). On discharge, fewer CI patients received ticagrelor
(P=0.04). There is no difference in time from presentation to
percutaneous coronary intervention (PCI), periprocedural
complication rate, or the total length of hospital stay in CI
patients compared with the normal group (Table S1).
Clinical Outcomes
One-year follow-up outcome was successfully ascertained for
270 study participants (Table 2), 1 patient was lost to follow-up.
At 1 year, CI patients were associated with a signiﬁcantly
greater likelihood of reaching MACE outcome by Kaplan–Meier
survival analysis (Figure 2) versus patients with normal cogni-
tion (P=0.047 by Log-rank test), and had a signiﬁcantly
increased hazard of incidence of MACE (hazard ratio 1.61,
95% conﬁdence interval [95% CI] 1.00– 2.57, P=0.049). One
patient in the CI group required dialysis at 1 year, and 2
individuals in the CI group became dependent on institutional
care. There were 88 (32.6%) patients who had 1 or more
hospital readmission events during the 1-year follow-up period;
the ﬁrst rehospitalization event was taken into account if
multiple admissions occurred. Over a third (n=33, 37.5%) of
admissions were because of problems with the cardiovascular
system. No difference was found between the normal cognition
group and the CI group in cardiovascular system readmission
rate (12.8% versus 13.9%, P=0.79), or total any-cause readmis-
sion rate (33.8% versus 37.4%, P=0.56).
Cognitive Decline Analysis
Two hundred eleven patients completed the 1-year follow-up
cognitive assessment. MoCA was not obtained in the
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remaining patients at 1 year for the following reasons: 12
died, 39 were followed up by general practitioner letter, 8 had
telephone follow-up, and 1 patient was lost to follow-up. There
is a signiﬁcant reduction in overall MoCA score from baseline
to 1-year follow-up (mean reduction in score: 0.63.3;
25.43.2 versus 24.73.7, baseline versus 1-year MoCA
Figure 1. Flow diagram of ICON-1 screening, recruitment, and cognition subgroup analysis. ACS indicates acute coronary
syndrome; GP, general practitioner; ICON-1, Study to Improve Cardiovascular Outcomes in High Risk Patients With Acute
Coronary Syndrome.
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Table 1. Baseline Characteristics Stratiﬁed by Baseline Cognitive Status
Total (n=271) Normal (n=141) Cognitive Impairment (n=130) P Value
Demographics
Age, y (SD) 80.5 (4.8) 79.4 (4.8) 81.6 (4.5) <0.001*
Male, n (%) 169 (62.4) 93 (66.0) 76 (58.5) 0.20
Clinical measures
Height, m (SD) 1.66 (0.1) 1.67 (0.1) 1.65 (0.11) 0.25
Weight, kg (SD) 75.3 (14.3) 76.1 (14.5) 74.4 (13.8) 0.18
BMI, kg m2 (SD) 27.4 (4.7) 27.5 (5.0) 27.3 (4.3) 0.74
Heart rate, bpm (IQR) 70 (21) 69 (18) 73.5 (21) 0.13
Systolic BP, mm Hg (SD) 144 (25) 143 (25) 145 (26) 0.67
Diastolic BP, mm Hg (SD) 77 (14) 76 (14) 78 (14) 0.30
Killip class II and above, n (%) 29 (11.7) 10 (7.6) 19 (16.4) 0.03*
ST changes present, n (%) 76 (32.1) 31 (25.2) 45 (39.5) 0.02*
NYHA III or IV, n (%) 55 (20.3) 16 (11.3) 39 (30.0) <0.001*
CCS III or IV, n (%) 40 (14.8) 16 (11.3) 24 (18.5) 0.1
GRACE Score, points (SD) 129.9 (19.4) 125.9 (17.5) 134.5 (20.4) 0.001*
Medical history
Hypertension, n (%) 195 (72.0) 102 (72.3) 93 (71.5) 0.88
Diabetes mellitus, n (%) 65 (24.0) 35 (24.8) 30 (23.1) 0.74
Hyperlipidemia, n (%) 158 (58.3) 85 (60.3) 73 (56.2) 0.49
Family history of IHD, n (%) 84 (31.2) 46 (33.1) 38 (29.2) 0.50
Renal impairment, n (%) 53 (19.6) 20 (14.2) 33 (25.4) 0.02*
Previous MI, n (%) 90 (33.2) 38 (27.0) 52 (40.0) 0.02*
Previous angina, n (%) 112 (41.3) 51 (36.2) 61 (46.9) 0.07
Previous PCI, n (%) 54 (19.9) 24 (17.0) 30 (23.1) 0.21
Previous CABG, n (%) 15 (5.5) 7 (5.0) 8 (6.2) 0.67
CCF, n (%) 21 (7.7) 7 (5.0) 14 (10.8) 0.07
AF, n (%) 40 (14.8) 19 (13.5) 21 (16.2) 0.54
PVD, n (%) 27 (10.0) 10 (7.1) 17 (13.1) 0.10
Previous TIA/stroke, n (%) 43 (15.9) 16 (11.3) 27 (20.8) 0.03*
Arthritis, n (%) 90 (33.2) 44 (31.2) 46 (35.4) 0.47
COPD, n (%) 48 (17.7) 22 (15.6) 26 (20.0) 0.34
Malignancy, n (%) 28 (10.0) 10 (7.1) 17 (13.1) 0.10
Peptic ulcer disease, n (%) 14 (5.2) 7 (5.0) 7 (5.4) 0.88
Bleeding problems, n (%) 7 (2.6) 4 (2.8) 3 (2.3) 1.0
Anemia, n (%) 20 (7.4) 6 (4.3) 14 (10.8) 0.04*
Smoking status
Current smoker, n (%) 19 (7.1) 9 (6.5) 10 (7.7) 0.70
Ex-smoker, n (%) 132 (49.1) 67 (48.2) 65 (50.0) 0.77
Never-smoker, n (%) 117 (43.5) 64 (45.3) 54 (41.5) 0.53
Frailty indices
Fried index, score (IQR) 1 (2) 1 (1) 2 (2) 0.003*
Weight loss, n (%) 73 (26.9) 34 (24.1) 39 (30.0) 0.28
Continued
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score, P=0.007 using paired t test) (Figure 3A and 3B).
Seventy-four (35.1%) patients had cognitive decline (MoCA
score dropped by ≥2 points), and they were deﬁned as
“decliners.” The remaining 137 patients were deﬁned as
“nondecliners.” Decliners had higher MoCA scores at baseline
compared with nondecliners (26.2 versus 24.9, P=0.001), had
less proportion of nonsmokers (P=0.001), more likely to be
frail, with low physical activity (P=0.02) and slow walking
speed (P=0.04) in Fried frailty measurement domains
(Table S2). The presentation and management strategy were
similar for decliners and nondecliners.
The rate of having an MI within 1-year follow-up was
signiﬁcantly higher in decliners (14.9% versus 5.1%, P=0.02),
and they also had a higher proportion with congestive cardiac
failure (14.9% versus 3.6%, P=0.003) (Table S3). In logistic
regression analysis (Table S4), recurrentMIwas an independent
predictor of cognitive decline at 1 year (odds ratio 3.24, 95% CI
1.2–8.76, P=0.02), and this remained signiﬁcant in age and sex
adjusted model (odds ratio 3.19, 95% CI 1.18–8.63, P=0.02)
and also after adjustment for other confounders. Other
signiﬁcant fully adjusted predictors of cognitive decline
included new or worsening congestive cardiac failure within 1
year (P=0.008), all-cause rehospitalization within 1 year
(P=0.02), and slow walking (P=0.045) at baseline. Additional
linear regression analysis was also used to identify predictors of
change in MoCA score at 1 year, controlling for baseline MoCA
score. Recurrent MI was one of the signiﬁcant predictors of
MoCA change with a b coefﬁcient of 2.63 (P=0.048) indicating
patients who had a recurrent MI would expect to have a decline
in MoCA score by 2.63 at 1 year.
Discussion
The present study demonstrates that in older patients
undergoing invasive management of NSTEACS, there is a
high prevalence of undiagnosed cognitive impairment at
baseline. Our data showed that this group of NSTEACS
patients had a lower than normal MoCA performance score
(mean score 25.4 versus 25.7 from normative study13). Our
study also shows that cognitive decline is present in over a
third of all participants and recurrent MI is independently
associated with cognitive decline at 1 year.
Very few prior studies have evaluated cognitive function in
the setting of acute MI. Gharacholou and colleagues recruited
patients who had survived an acute MI (mean age
Table 1. Continued
Total (n=271) Normal (n=141) Cognitive Impairment (n=130) P Value
Physical endurance/energy, n (%) 78 (28.8) 37 (26.2) 41 (31.5) 0.34
Low physical activity, n (%) 93 (34.3) 41 (29.1) 52 (40.0) 0.06
Weakness, n (%) 169 (62.4) 79 (56.0) 90 (69.2) 0.03*
Slow walking speed/TUG, n (%) 38 (14.1) 11 (7.8) 27 (21.1) 0.002*
Fried frailty status
Robust, n (%) 53 (19.6) 29 (20.6) 24 (18.5) 0.002*
Prefrail, n (%) 148 (54.6) 88 (62.4) 60 (46.2)
Frail, n (%) 70 (25.8) 24 (17.0) 46 (35.4)
Rockwood index, score (IQR) 3 (2) 3 (1) 4 (1) <0.001*
Rockwood frailty status
Nonfrail 239 (88.2) 133 (94.3) 106 (81.5) 0.001*
Frail 32 (11.8) 8 (5.7) 24 (18.5)
Blood results
Hemoglobin, g L1 (SD) 131.2 (19.1) 133.4 (20.7) 128.7 (16.9) 0.02*
Creatinine, lmol L1 (SD) 101.9 (33.5) 97.1 (27.3) 107.1 (38.5) 0.07
eGFR, % (SD) 55.4 (20.3) 58.4 (18.3) 52.1 (22.0) 0.001*
Hs CRP, mg L1 (IQR) 4.15 (8.3) 3.2 (6.9) 4.45 (10.3) 0.049*
Troponin T, ng L1 (IQR) 120 (371) 124 (378) 119 (370) 0.43
AF indicates atrial ﬁbrillation; BMI, body mass index; BP, blood pressure; bpm, beats per minute; CABG, coronary artery bypass graft; CCF, congestive cardiac failure; CCS, Canadian
Cardiovascular Society angina score; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; GRACE, Global Registry of Acute Coronary Events; Hs CRP,
high-sensitivity C-reactive protein; IHD, ischemic heart disease; IQR, interquartile range; MI, myocardial infarction; NYHA, New York Heart Association class; PCI, percutaneous coronary
intervention; PVD, peripheral vascular disease; TIA, transient ischemic attack; TUG, timed up and go test.
*P < 0.05.
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73.26.3 years, 58.5% men) in the TRIUMPH (the Transla-
tional research investigating underlying disparities in acute
myocardial infarction patients’ health status) study, which
showed a high rate of CI (55.6%) and a signiﬁcant higher risk-
adjusted 1-year mortality (hazard ratio 1.97, P=0.05).14
Volonghi and colleagues compared cognitive outcomes in
ACS to transient ischemic attack and minor stroke patients
(ACS group: mean age 68.112.4 years, 73% men) in the
OXVASC (Oxford Vascular Study). A high prevalence of CI
(49%) at 1 year in ACS patients was found, and the ACS group
had a higher risk of CI than transient ischemic attack patients
but a risk similar to that of the minor stroke group.15 A
German study conducted by Salzwedel and colleagues
recruited 496 younger patients (mean age 54.46.3 years,
79.8% men) who had a recent acute coronary event (ACE-MI
or coronary artery bypass graft) and reported a CI rate of
36.7%, CI was also found to be associated with heavy
workloads and a longer sick leave before ACE.16 The
TRIUMPH and OXVASC studies utilized a cognitive assess-
ment tool, TICS-m (the Telephone interview for cognitive
status-modiﬁed) different from MoCA to determine cognitive
status. Salzwedel et al utilized MoCA as their cognitive
assessment tool, but they studied a much younger patient
group (mean age 54.4 years), which may explain the lower CI
rate. Timing of the baseline cognitive assessment was also
slightly different: ICON-1 at index NSTEACS event during
hospitalization; TRIUMPH at 1 month after acute MI; OXVASC
at 1-year post MI follow-up; and Salzwedel’s study at 14 days
after discharge following MI or coronary artery bypass graft.
The current study showed a signiﬁcant reduction in overall
MoCA score over 1 year with a mean reduction of 0.6. This is
a more than expected decline in cognitive function compared
with normative longitudinal studies on MoCA performance
(annualized MoCA change of 0.37 from healthy elderly
Table 2. One-Year Outcomes, Stratiﬁed by Baseline Cognition Status
1-Year Outcomes Total (n=270) Normal (n=141) Cognitive Impairment (n=129) P Value
MACE outcome, n (%) 71 (26.3) 30 (21.3) 41 (31.8) 0.05*
Death, n (%) 13 (4.8) 4 (2.8) 9 (7) 0.16
Myocardial infarction, n (%) 30 (11.6) 13 (9.4) 17 (14) 0.25
Death/myocardial infarction, n (%) 39 (14.4) 15 (10.6) 24 (18.6) 0.06
Urgent revascularization, n (%) 21 (8.1) 7 (5.1) 14 (11.6) 0.06
Stroke, n (%) 2 (0.8) 0 (0) 2 (1.7) 0.22
Significant bleeding, n (%) 36 (14) 18 (13) 18 (15) 0.65
Stable angina, n (%)† 63 (26.8) 31 (24.6) 32 (29.4) 0.41
Elective PCI, n (%)† 26 (10.6) 16 (12.3) 10 (8.7) 0.36
CCF, n (%)† 24 (10) 10 (7.8) 14 (12.5) 0.23
TIA, n (%)† 2 (0.8) 1 (0.8) 1 (0.9) 1
Dialysis, n (%)† 1 (0.4) 0 (0) 1 (0.9) 0.47
Institutional care requirement, n (%)† 2 (0.9) 0 (0) 2 (1.9) 0.22
CCF indicates congestive cardiac failure; MACE, major adverse cardiac events (including death, myocardial infarction, urgent revascularization, stroke, signiﬁcant bleeding); PCI,
percutaneous coronary intervention; TIA, transient ischemic attack.
*Statistically signiﬁcant P < 0.05.
†Secondary outcomes.
A full description of statistical methods is included in the main text. Note: the composite endpoint only counts the ﬁrst event; some patients experienced multiple adverse outcomes.
Figure 2. Kaplan–Meier plot, demonstrating time to ﬁrst MACE
stratiﬁed by baseline cognitive status. Log-rank test for equality of
survival distributions demonstrates a signiﬁcant difference
between the survival curves (v2=3.96, 1 degree of freedom,
P=0.047). MACE indicates major adverse cardiovascular events
(death, nonfatal myocardial infarction, urgent revascularization,
stroke, and signiﬁcant bleeding).
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individuals13). Over one third of participants were identiﬁed as
“decliners” with an overall MoCA reduction ≥ 2. Interestingly
cognitive decline was common in patients who had a higher
baseline cognitive function, those who were smokers, frail,
had less physical activity, and slower walking speed. The
important ﬁnding in the present analysis is that recurrent MI
was independently associated with cognitive decline at 1 year.
A recently published Danish large population-based cohort
study demonstrated previous MI is associated with higher risk
of vascular dementia (hazard ratio=1.35, 95% CI 1.28–1.43),
and this association is strengthened for patients who had a
stroke after MI (hazard ratio=4.48, 95% CI 3.29–6.12).17
THORESCI (Tilburg Health Outcomes Registry or Emotional
Stress after Coronary Intervention) study found that patients
treated with acute PCI for ACS had poorer concentration
(P=0.019) compared with elective PCI patients those who
were more depressed and had a higher level of fatigue had
poorer concentration and attention.18 A recent systematic
review found that coronary heart disease (CHD-MI and angina
pectoris combined) was associated with a 45% increased risk
of dementia, cognitive impairment, or cognitive decline (odds
ratio 1.45, 95% CI 1.2–1.74, P<0.001), and MI was found to
be associated with a 46% increased risk (odds ratio 1.46, 95%
CI 1.16–1.84, P=0.001).19
The exact pathophysiological mechanism by which CAD is
related to risk of cognitive decline or dementia is still
unknown, but several possible pathways have been proposed.
The association of dementia and CAD can be partly explained
by their shared risk factors, such as diabetes mellitus,
smoking, hypertension, hypercholesterolemia, and obesity.
Higher platelet activation in CAD patients with cognitive
impairment has been reported previously.20 This leads to
proposed hypothetical mechanisms involving increased plate-
let activity in CAD patients triggering perivascular inﬂamma-
tion in the brain and progression of carotid artery diseases
and cerebral vasoconstriction contributing to dementia
progression.21 A recent study suggested immune activation
might interconnect heart and brain dysfunction in the setting
of MI.22 CAD and associated vascular disease can lead to
cerebrovascular changes and resulting in cerebral hypoperfu-
sion, which in turn can lead to poor cognitive function and
dementia. There are very few small studies evaluating PCI-
related cognitive decline, and ﬁndings have been inconsistent.
The passage of cardiac catheters in coronary angiography or
PCI can potentially dislodge atheroma from the aortic wall,
which leads to microemboli to the cerebral circulation causing
stroke or cognitive decline.23 Devapalasundarum et al found
that cognitive function was worse in patients having elective
coronary angiography compared with healthy controls: a rate
of 39.6% new cognitive dysfunction was reported at discharge
in coronary angiography patients. The group hypothesized
that cognitive dysfunction may be exacerbated in some
patients because of periprocedural microemboli.24
In our study, frail patients experienced CI, and this is
particularly reﬂected in the domains of weak handgrip, slow
walking, and low physical activity. This is possibly because of
common underlying pathophysiologic mechanisms, and the
concept of cognitive frailty has been proposed to emphasize
the important role of brain aging. In the frail elderly population
with cognitive deﬁcits but without dementia, this may
represent a prodromal phase for neurodegenerative diseases
and is a potential target for early intervention to prevent
disease progression.25
Dementia is associated with a huge burden on health and
social care. Risk factor modiﬁcation is crucially important in
preventing cognitive decline to ensure good quality of life and
to maintain functional independence, as well as to save
healthcare costs. Our study has demonstrated the association
of recurrent MI and cognitive decline. Thus, more aggressive
Figure 3. A, Histogram of the change in MoCA score from
baseline to follow-up. B, Parallel boxplots of the overall change in
mean MoCA score at 1 year from baseline split by baseline
cognition. MoCA indicates Montreal Cognitive Assessment.
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contemporary therapeutic strategies to prevent recurrent
events might play a role in reducing cognitive decline and
subsequently delaying progression into dementia, and the
older patients should not be denied advanced care with
contemporary treatment strategies.
Study Limitations
This study has limitations. ICON-1 recruited patients who had
been referred to tertiary cardiac centers for coronary angiog-
raphy, and thus the oldest, frailest, and more cognitively
impaired patients who were not offered invasive management
were not included in our study. Furthermore, the current study
aimed to reﬂect real-world acute state of cognitive faculties at
the time of NSTEACS, and cognitive impairment was assessed
at the time of index hospitalization. Performing objective
cognitive assessment could be challenging during acute illness,
as patients are prone to acute confusional states or delirium.
However, an effort was made to exclude conditions that may
predispose patients to delirium (active infection, conditions that
can cause brain hypoperfusion: cardiac arrest, ventricular
arrhythmia or cardiogenic shock, and moderate to severe
valvular heart disease). Moreover, applying a MoCA cut-off
score of 26 to the older patients may seem to be too stringent,
because normative studies in this elderly population suggest an
age-adjusted or education-adjusted cut-off score to be
applied.13,26 There is currently no randomized controlled trial
comparing cognitive function or decline in elderly patients with
acute MI treated with PCI versus optimal medical therapy. The
British Heart Foundation older patients in the SENIOR-RITA
(non-ST segment elevation myocardial infarction randomized
interventional treatment) trial (ClinicalTrials.gov identiﬁer:
NCT03052036) aims to compare invasive revascularization
versus optimal medical treatment for older patients with non-
ST–elevation myocardial infarction, and will provide some
important insight into frailty and cognitive function affected by
treatment strategy. Nevertheless, for the ﬁrst time, our study
provides key insights into baseline cognitive impairment and
cognitive decline in this patient cohort (older patients under-
going invasive care for NSTEACS). Our study demonstrated the
association between recurrent MI and cognitive decline,
highlighting the importance and the need for risk factor
modiﬁcation addressing recurrent MI in preventing the decline
in cognitive function and progression to dementia. There is also
a proportion of patients whose cognition improved. This is not
the focus of this study and may warrant further investigation.
Conclusions
In older patients undergoing invasive management of
NSTEACS, there is a high prevalence of cognitive impairment
at baseline. Recurrent MI is independently associated with
cognitive decline at 1 year. The actual mechanisms respon-
sible for cognitive decline in this patient cohort are not clear.
Several hypothetical theories on the complex relationship
between heart disease and long-term risk of dementia exist.
These can be taken into account for the cognitive decline in
this patient cohort. Early intervention and risk factor modi-
ﬁcations are crucial in preventing cognitive decline.
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SUPPLEMENTAL MATERIAL
Table S1. Procedural details and medical management. 
Total 
(n = 271) 
Normal 
 (n = 141) 
Cognitive impairment 
 (n = 130) 
P value 
NSTEMI, n (%) 219 (80.8) 114 (80.9) 105 (80.8) 0.99 
UA, n (%) 52 (19.2) 27 (19.1) 25 (19.2) 0.99 
Time from admission to CA, days (IQR) 5 (4) 5 (3) 5 (4) 0.31 
Length of hospital stay, days (IQR) 6 (5) 6 (4) 6 (4) 0.12 
Medical management only, n (%) 36 (13.3) 13 (9.2) 23 (17.7) 0.04 
PCI, n (%) 225 (83) 122 (86.5) 103 (79.2) 0.11 
CABG, n (%) 10 (3.7) 6 (4.3) 4 (3.1) 0.75 
Single-vessel PCI, n (%) 158 (58.3) 89 (63.1) 69 (53.1) 0.09 
Multi-vessel PCI, n (%) 67 (24.7) 33 (23.4) 34 (26.2) 0.6 
Left main stem disease, n (%) 16 (5.9) 4 (2.8) 12 (9.2) 0.03 
LAD disease, n (%) 130 (48.0) 71 (50.4) 59 (45.4) 0.41 
LCx disease, n (%) 75 (27.7) 37 (26.2) 38 (29.2) 0.58 
RCA disease, n (%) 77 (28.4) 42 (29.8) 35 (26.9) 0.6 
Number of stents, median (IQR) 1 (1) 1 (1) 1 (1) 0.68 
Radial access, n (%) 235 (86.7) 125 (88.7) 110 (84.6) 0.33 
Contrast volume, mL (SD) 160 (80) 171 (77) 148 (82) 0.006 
Radiation dose, cGycm2 (IQR) 5768 (5126) 6020 (5511) 5505 (5050) 0.16 
Periprocedural complication*, n (%) 14 (5.2) 6 (4.3) 8 (6.2) 0.48 
Duration of PCI, min (SD) 60.7 (29.8) 62.3 (29.1) 59.0 (30.6) 0.33 
Medications on Discharge 
Aspirin, n (%) 268 (98.9) 140 (99.3) 128 (98.5) 0.61 
Clopidogrel, n (%) 155 (57.2) 74 (52.5) 81 (62.3) 0.10 
Prasugrel, n (%) 2 (0.7) 1 (0.7) 1 (0.8) 1 
Ticagrelor, n (%) 105 (38.7) 63 (44.7) 42 (32.3) 0.04 
Statin, n (%) 260 (95.9) 132 (93.6) 128 (98.5) 0.06 
ACEi / ARB, n (%) 240 (88.6) 129 (91.5) 111 (85.4) 0.12 
β-blocker, n (%) 219 (80.8) 110 (78.0) 109 (83.8) 0.22 
Ca2+-channel blocker, n (%) 90 (33.2) 48 (34.0) 42 (32.3) 0.76 
Long-acting nitrate, n (%) 79 (29.2) 36 (25.5) 43 (33.1) 0.17 
Nicorandil, n (%) 40 (14.8) 17 (12.1) 23 (17.7) 0.19 
Proton pump inhibitor, n (%) 121 (44.6) 64 (45.4) 57 (43.8) 0.80 
Warfarin, n (%) 18 (6.6) 8 (5.7) 10 (7.7) 0.51 
NOAC, n (%) 8 (3.0) 3 (2.1) 5 (3.8) 0.49 
Vitamin D supplement, n (%) 32 (11.8) 18 (12.8) 14 (10.8) 0.61 
 
ACEi – angiotensin converting enzyme inhibitor, ACS – acute coronary syndrome, ARB – angiotensin 
II receptor blocker, CA – coronary angiography, Ca2+ – calcium, CABG – coronary artery bypass 
grafting, IQR – inter quartile range, LAD – left anterior descending artery, LCx – left circumflex artery, 
NOAC – novel oral anti-coagulant, NSTEMI – non-ST-elevation myocardial infarction, PCI – 
percutaneous coronary intervention, RCA – right coronary artery, SD – standard deviation, UA - 
unstable angina.  
* – Periprocedural complications: 7 arterial dissection (5 coronary artery dissection, 1 aortic artery 
dissection treated conservatively,1 iliac artery dissection), 1 loss of side branch, 1 coronary artery 
perforation, 1 bleeding from radial artery puncture site, 1 pseudoaneurysm, 1 retroperitoneal bleed 
required blood transfusion, 1 pulmonary oedema, 1 ventricular fibrillation (VF) arrest. 
 
Table S2. Baseline characteristics stratified by cognitive decliner (CD) or non-decliner (ND). 
 Total 
(n = 211) 
ND 
(n = 137) 
CD  
(n = 74) 
P 
value 
Demographics 
     Age, years (SD) 80.2 (4.9) 80.3 (4.6) 80.1 (5.4) 0.75 
     Male, n (%) 134 (63.5) 83 (60.6) 51 (68.9) 0.23 
Clinical Measures 
     Height, m (SD) 1.66 (0.1) 1.67 (0.1) 1.65 (0.1) 0.37 
     Weight, kg (SD) 75.9 (13.9) 76.1 (14.1) 75.5 (13.5) 0.79 
     BMI, kg m-2 (SD) 27.4 (4.3) 27.4 (4.4) 27.6 (4.0) 0.54 
     Heart rate, bpm (IQR) 70 (21) 71 (18) 67 (23) 0.24 
     Systolic BP, mmHg (SD) 144 (26) 144 (25) 144 (28) 0.87 
     Diastolic BP, mmHg (SD) 77 (13) 78 (13) 75 (14) 0.32 
     Killip class II and above, n (%) 22 (11.4) 13 (10.3) 9 (13.4) 0.52 
     ST changes present, n (%) 58 (30.9) 39 (31.5) 19 (29.7) 0.80 
     NYHA III or IV, n (%) 39 (18.5) 24 (17.5) 15 (20.3) 0.62 
     CCS III or IV, n (%) 29 (13.7) 17 (12.4) 12 (16.2) 0.44 
     GRACE Score, points (SD) 129.2 (19.4) 129.3 (18.4) 129.0 (21.4) 0.75 
Medical History 
     Hypertension, n (%) 150 (71.1) 92 (67.2) 58 (78.4) 0.09 
     Diabetes, n (%) 47 (22.3) 27 (19.7) 20 (27) 0.22 
     Hyperlipidaemia, n (%) 124 (58.8) 77 (56.2) 47 (63.5) 0.30 
     Family history of IHD, n (%) 65 (31.1) 45 (33.3) 20 (27) 0.35 
     Renal impairment, n (%) 42 (19.9) 32 (23.4) 10 (13.5) 0.09 
     Previous MI, n (%) 64 (30.3) 41 (29.9) 23 (31.1) 0.86 
     Previous angina, n (%) 81 (38.4) 48 (35) 33 (44.6) 0.17 
     Previous PCI, n (%) 41 (19.4) 26 (19) 15 (20.3) 0.82 
     Previous CABG, n (%) 8 (3.8) 4 (2.9) 4 (5.4) 0.46 
     CCF, n (%) 15 (7.1) 9 (6.6) 6 (8.1) 0.68 
     AF, n (%) 30 (14.2) 17 (12.4) 13 (17.6) 0.31 
     PVD, n (%) 19 (9) 13 (9.5) 6 (8.1) 0.74 
     Previous TIA/Stroke, n (%) 31 (14.7) 19 (13.9) 12 (16.2) 0.65 
     Arthritis, n (%) 72 (34.1) 43 (31.4) 29 (39.2) 0.25 
     COPD, n (%) 33 (15.6) 20 (14.6) 13 (17.6) 0.57 
     Malignancy, n (%) 23 (10.9) 12 (8.8) 11 (14.9) 0.17 
     Peptic ulcer disease, n (%) 10 (4.7) 5 (3.6) 5 (6.8) 0.33 
     Bleeding problems, n (%) 3 (1.4) 2 (1.5) 1 (1.4) 1 
     Anaemia, n (%) 14 (6.6) 10 (7.3) 4 (5.4) 0.78 
Smoking Status 
     Current smoker, n (%) 12 (5.7) 6 (4.4) 6 (8.2) 0.35 
     Ex-smoker, n (%) 102 (48.8) 59 (43.4) 43 (58.9) 0.03 
     Never-smoker, n (%) 94 (45) 70 (51.5) 24 (32.9) 0.01 
Frailty Indices 
     Fried index, score (IQR) 1 (1) 1 (1) 2 (2) 0.07 
Weight loss, n (%) 54 (25.6) 32 (23.4) 22 (29.7) 0.31 
Physical endurance/energy, n 
(%) 
54 (25.6) 32 (23.4) 22 (29.7) 0.31 
Low physical activity, n (%) 59 (28) 31 (22.6) 28 (37.8) 0.02 
Weakness, n (%) 129 (61.1) 84 (61.3) 45 (60.8) 0.94 
Slow walking speed/TUG, n (%) 24 (11.5) 11 (8.1) 13 (17.6) 0.04 
     Fried frailty status: Robust, n (%) 48 (22.7) 33 (24.1) 15 (20.3)  
0.63                       Prefrail, n (%) 116 (55) 76 (55.5) 40 (54.1) 
                      Frail, n (%) 47 (22.3) 28 (20.4) 19 (25.7) 
     Charlson index, points (IQR) 5 (2) 5 (2) 5 (2.3) 0.87 
Blood Results 
     Haemoglobin, g L-1 (SD) 132.3 (19.4) 132.1 (20.4) 132.8 (17.6) 0.98 
     Creatinine, µmol L-1 (SD) 100.6 (32.7) 99.7 (32.0) 102.1 (34.2) 0.51 
     eGFR, % (SD) 56.8 (20.5) 57.5 (21.5) 55.5 (18.6) 0.69 
     Hs CRP, mg L-1 (IQR) 3.95 (8.5) 4.2 (9.8) 3.9 (7) 0.96 
     Troponin T, ng L-1 (IQR) 121 (381) 126 (360.5) 99 (431.8) 0.89 
 
AF – atrial fibrillation, BMI – body mass index, BP – blood pressure, CABG – coronary artery bypass 
grafting, CCF – congestive cardiac failure, CCS – Canadian Cardiovascular Society angina score, 
COPD – chronic obstructive pulmonary disease, eGFR – estimated glomerular filtration rate, GRACE 
– Global Registry of Acute Coronary Events, Hs CRP – high-sensitivity C-reactive protein, IHD –
ischaemic heart disease, IQR – interquartile range, MI – myocardial infarction, NYHA – New York 
Heart Association class, PCI – percutaneous coronary intervention, PVD – peripheral vascular disease, 
SD – standard deviation, TIA – transient ischaemic attack, TUG – timed up and go test. 
 
Table S3. 1-year outcomes, stratified by cognitive decline status. 
1-year Outcomes Total 
(n = 211) 
Non-decliner 
(n = 137) 
Cognitive decliner 
(n = 74) 
P-value 
     MACE outcome- n (%) 46 (21.8) 25 (18.2) 21 (28.4) 0.09 
     Myocardial infarction- n (%) 18 (8.5) 7 (5.1) 11 (14.9) 0.02 
     Urgent revascularisation- n (%) 14 (6.6) 7 (5.1) 7 (9.5) 0.25 
     Stroke- n (%) 1 (0.5) 1 (0.7) 0 (0) 1 
     Significant bleeding- n (%) 35 (16.6) 23 (16.8) 12 (16.2) 0.92 
     Stable angina- n (%) 53 (25.1) 30 (21.9) 23 (31.1) 0.14 
     Elective PCI- n (%) 20 (9.5) 14 (10.2) 6 (8.1) 0.62 
     CCF- n (%) 16 (7.6) 5 (3.6) 11 (14.9) 0.003 
     TIA- n (%) 2 (0.9) 1 (0.7) 1 (1.4) 1 
 
CCF – congestive cardiac failure, MACE – major adverse cardiac events (including death, myocardial 
infarction, urgent revascularisation, stroke, significant bleeding), PCI – percutaneous coronary 
intervention, TIA – transient ischaemic attack.  
A full description of statistical methods is included in the main text. Note: the composite endpoint only 
counts the first event; some patients experienced multiple adverse outcomes 
 
Table S4. Predictors of cognitive decline at 1-year, unadjusted and adjusted logistic regression 
models. 
 
ACS – acute coronary syndrome, CCF – congestive cardiac failure, CI – confidence interval, CVS – 
cardiovascular system, MI –  myocardial infarction, OR – odds ratio 
* Unadjusted logistic regression models 
† Logistic regression models adjusted for age (age≥85 vs. age<85) and sex (male vs. female) 
‡ Logistic regression models adjusted for age (age≥85 vs. age<85), sex (male vs. female) and baseline 
MoCA (<26 vs. ≥26) 
Predictor Unadjusted* Adjusted† Adjusted‡ Adjusted§ 
OR (95% CI) P 
value 
OR (95% CI) P 
value 
OR (95% CI) P 
value 
OR (95% CI) P 
value 
Recurrent MI 3.24 (1.2, 8.76) 0.02 3.19 (1.18, 8.63) 0.02 3.17 (1.15, 8.79) 0.03 4.33 (1.48, 12.66) 0.007 
Unplanned 
repeat 
revascularisati
on 
1.94 (0.65, 5.76) 0.23 1.91 (0.64, 5.71) 0.25 2.08 (0.68, 6.36) 0.20 2.29 (0.73, 7.16) 0.15 
Bleeding 0.96 (0.45, 2.06) 0.92 1.02 (0.46, 2.27) 0.96 1.03 (0.45, 2.33) 0.95 0.96 (0.41, 2.27) 0.93 
CCF- new or 
worsening 
4.61 (1.54, 13.83) 0.006 4.54 (1.51, 
13.63) 
0.007 5.22 (1.68, 16.27) 0.004 4.82 (1.51, 15.36) 0.008 
All cause re- 
Hospitalisation 
1.85 (1.03, 3.33) 0.04 1.88 (1.04, 3.39) 0.04 1.94 (1.06, 3.55) 0.03 2.15 (1.14, 4.06) 0.02 
CVS 
hospitalisation 
1.53 (0.66, 3.58) 0.32 1.57 (0.66, 3.72) 0.31 1.50 (0.62, 3.61) 0.37 1.70 (0.69, 4.20) 0.25 
Baseline 
cognitive 
impairment 
0.40 (0.22, 0.72) 0.002 0.41 (0.22, 0.74) 0.003 - - 0.36 (0.19, 0.68) 0.002 
Baseline Fried 
frailty 
1.35 (0.69, 2.62) 0.38 1.44 (0.73, 2.84) 0.30 1.79 (0.87, 3.67) 0.11 1.09 (0.52, 2.27) 0.83 
Weight loss 1.39 (0.74, 2.62) 0.31 1.50 (0.78, 2.86) 0.22 1.6 (0.83, 3.11) 0.16 1.33 (0.66, 2.68) 0.43 
Physical 
endurance 
1.39 (0.74, 2.62) 0.31 1.41 (0.74, 2.68) 0.29 1.51 (0.78, 2.92) 0.22 1.21 (0.61, 2.40) 0.59 
Low physical 
activity 
2.08 (1.12, 3.86) 0.02 2.04 (1.10, 3.79) 0.023 2.19 (1.16, 4.15) 0.016 1.62 (0.84, 3.13) 0.15 
Weakness 0.98 (0.55, 1.75) 0.94 1.03 (0.57, 1.86) 0.93 1.17 (0.63, 2.14) 0.62 0.96 (0.51, 1.78) 0.89 
Slow walking 2.40 (1.02, 5.67) 0.046 2.36 (1.0, 5.58) 0.05 3.27 (1.31, 8.19) 0.011 2.57 (1.02, 6.45) 0.045 
Smoking 
history 
2.17 (1.20, 3.92) 0.011 2.23 (1.23, 4.05) 0.008 2.51 (1.35, 4.64) 0.004 - - 
Vitamin D 
supplement 
2.43 (1.06, 5.58) 0.04 3.07 (1.27, 7.45) 0.013 3.06 (1.24, 7.56) 0.016 - - 
Hypertension 1.77 (0.92, 3.43) 0.088 1.75 (0.91, 3.39) 0.096 1.80 (0.92, 3.52) 0.089 - - 
Renal 
impairment 
0.51 (0.24, 1.11) 0.09 0.52 (0.24, 1.14) 0.10 0.59 (0.27, 1.31) 0.20 - - 
§ Logistic regression models adjusted for age (age≥85 vs. age<85), sex (male vs. female), smoking 
history (current/ex-smoker vs. never smoker), hypertension, renal impairment, and taking Vitamin D 
supplement 
|| Linear regression models adjusted for age, sex, and baseline MoCA score 
 
 
 
 
 
 
 
 
